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We compared the eﬀects of gliclazide, an antidiabetic agent with antioxidant properties, and N-acetyl-L-cysteine (NAC), a
glutathione precursor, in protecting against 2-deoxy-d-ribose- (dRib-) induced oxidative damage in HIT-T15 cells. Using trypan
blue staining and ﬂow cytometry with annexin V/PI staining, gliclazide treatment slightly reversed dRib-induced cell death and
apoptosis, and NAC treatment markedly reduced both measures. Likewise, ﬂow cytometry using DHR 123 staining showed that
the levels of dRib-induced reactive oxygen species (ROS) were partially suppressed by gliclazide and completely inhibited by NAC.
Using electron spin resonance spectrometry, gliclazide and NAC scavenged hydroxyl radicals generated by Fenton reaction to a
similardegreeinacell-freesystem.NAC,butnotgliclazide,completelyrestoredtheintracellularglutathionedepletedbydRibusing
monochlorobimane ﬂuorescence and glutathione assays. Thus, gliclazide treatment suppressed dRib-induced oxidative damage in
HIT-T15 cells less than NAC did because gliclazide did not restore the intracellular glutathione content as eﬀectively as NAC.
In addition, the elevation of intracellular glutathione rather than free radical scavenging might be an important mechanism for
protecting against dRib-induced oxidative damage in a β-cell line.
1.Introduction
Pancreatic β-cell function and mass decline progressively
withtimeinindividualswithtype2diabetes.Oxidativestress
seems to be one of the causes. 2-Deoxy-d-ribose (dRib) is
a powerful reducing sugar that rapidly increases oxidative
stress and apoptosis in pancreatic β-cells [1, 2]. This dRib-
induced oxidative damage was completely prevented by
adding N-acetyl-l-cysteine (NAC), known as a glutathione
precursor [1]. Gliclazide is an insulin secretagogue that
belongs to a second-generation sulfonylurea. It also has
antioxidant properties, independent of its glucose-lowering
eﬀect [3]. In an in vitro study, gliclazide has shown a
direct free radical-scavenging eﬀect that is not found in
glibenclamide [4, 5]. Plasma oxidative stress markers, low-
density lipoprotein (LDL) oxidation, and platelet aggrega-
tion have been signiﬁcantly improved in gliclazide-treated
patients with diabetes compared with groups treated with
other sulfonylureas [6–8].
The purpose of our study was to investigate whether
gliclazide could prevent dRib-induced oxidative damage in a
pancreatic β-cell line. In addition, we attempted to elucidate
the antioxidative mechanism of gliclazide by comparing its
eﬀects with those of NAC on dRib-induced oxidative stress
and apoptosis in a β-cell line.
2.MaterialsandMethods
2.1. Materials. Gliclazide, NAC, dihydrorhodamine 123
(DHR 123), dimethylsulfoxide (DMSO), 5, 5-dimethyl-1-
pyrroline-N-oxide (DMPO), FeSO4,a n dH 2O2 were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). dRib,
trypan blue, and monochlorobimane (mBCl) were obtained
from Amresco (Solon, OH, USA). Hydrochloric acid and
ethanol were from Merck (Darmstadt, Germany). RPMI-
1640, phenol red-free RPMI-1640, Dulbecco’s phosphate-
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Figure1:EﬀectsofgliclazideandNACondRib-triggeredcelldeath.
HIT-T15 cells were preincubated with gliclazide or NAC for 30min
at the indicated concentrations and then cultured with 35mM dRib
for 24h. Cell viability was determined by trypan blue exclusion
assays. Data are expressed as the mean ± SD of the percentage
of viable cells relative to the controls treated with vehicle (0.04%
DMSO). This experiment was performed twice, in quadruplicate.
∗∗P<0.01 versus vehicle-treated control; ††P<0.01 versus 35mM
dRib group tested by one-way ANOVA with Duncan’s post hoc test.
were from Gibco Invitrogen (Grand Island, NY, USA). Fetal
bovine serum (FBS) was from HyClone (Logan, UT, USA).
All culture dishes were from BD Falcon (Franklin Lakes, NJ,
USA).
2.2. Cell Culture. Insulin-secreting HIT-T15 cells were pro-
videdbytheKoreanCellLineBank(Seoul,Korea).Cellswere
cultured in RPMI-1640 medium supplemented with 10%
FBS, 100mU/mL penicillin, and 100mg/mL streptomycin.
The cultures were maintained at 37◦C in a humidiﬁed 5%
CO2 atmosphere and subcultured by trypsinization with
0.05% trypsin—0.02% EDTA in Ca2+-a n dM g 2+-free DPBS
when they reached about 70% conﬂuence. Two days after
subculture, the culture medium was replaced with fresh
RPMI-1640 containing 10% FBS, and 35 or 50mM dRib
was added to the medium after pretreatment with various
concentrations of gliclazide or 1mM NAC for 30min. The
cultures were then incubated for 6 or 24h.
2.3. Assessment of Cell Viability. Cells were cultured in 24-
well plates at a density of 1 × 105 per well. They were
incubated with 35mM dRib for 24h, with or without
gliclazide or NAC. Then, cells were harvested and stained
vitally with 0.4% trypan blue for 5min. In the sample
transferred to a hemocytometer, dead cells that did not
excludethedyeandviablecellsthatexcludeditwerecounted.
The results were expressed as the percentage of viable cells in
the whole population.
2.4. Flow Cytometry for Measuring Apoptosis. Aﬂ o wc y t o -
metric analysis with annexin V and propidium iodide (PI)
double staining was performed as described [2]. HIT-T15
c e l l sw e r ec u l t u r e di n6 - w e l lp l a t e sa tad e n s i t yo f5×
105 per well. The cells were stimulated with 50mM dRib
and gliclazide or NAC for 24h. Results were calculated as
the mean ﬂuorescence intensity and expressed as the fold
diﬀerence from the control group treated with vehicle alone
(0.04% DMSO).
2.5. Assessment of Intracellular Reactive Oxygen Species (ROS)
Levels. Intracellular ROS levels were assessed using the
ﬂuorescein-labeled dye DHR 123 as described [2]. HIT-T15
cells were plated in 6-well culture plates at a density of 5 ×
105 per well. The cells were stimulated with 50mM dRib and
gliclazide or NAC for only 6h because extensive cell death
could interfere with ROS measurement.
2.6. Assessment of Hydroxyl Radical-Scavenging Activity.
Electron spin resonance (ESR) spectroscopy was used
for assessing hydroxyl radical-scavenging activity in vitro.
Hydroxyl radicals were generated by the iron-catalyzed Fen-
ton reaction and reacted quickly with the spin trap DMPO.
Levels of the resultant DMPO-hydroxyl radical adducts were
measured using an ESR spectrometer (JEOL, Tokyo, Japan).
Gliclazide or NAC was ﬁrst dissolved in ethanol and then
diluted with DPBS (pH 7.4). The reaction mixtures for ESR
analysis consisted of 0.2mL of 0.3M DMPO, 0.2mL of
10mMFeSO4,0.2mLof10mMH2O2,and0.2mLofcontrol
vehicle (ethanol) or samples (gliclazide or NAC dissolved
in ethanol) incubated at room temperature for 2.5min.
The spectrometer conditions were magnetic ﬁeld 336.5mT,
power 1.00mW, frequency 9.4380GHz, modulation ampli-
tude 0.2mT, gain 200, scan time 0.5min, scan width 10mT,
sampling time constant 0.03s, and temperature 25◦C. The
ESR signal intensities of gliclazide and NAC groups were
estimated by comparison with an ethanol-treated control
group.
2.7. Measurement of Intracellular Glutathione Levels. The
content of intracellular reduced glutathione (GSH) was
assessed using a ﬂuorescent dye, mBCl. GSH binds speciﬁ-
c a l l yt om B C lt of o r maﬂ u o r e s c e n tG S H - m B C la d d u c ti na
reaction mediated by intracellular glutathione S-transferases
[9]. HIT-T15 cells were plated in 96-well culture plates at
a density of 1 × 104 per well. The cells were preincubated
with gliclazide or NAC for 30min and then cultured with
35mM dRib for only 6h because cell death could interfere
with GSH measurements. The stock solution of 100mM
mBClwaspreparedinDMSO,whichwasfurtherdissolvedin
phenol red-free RPMI-1640 medium at a ﬁnal concentration
of 5mM for use in experiments. Then, 2μL of 5mM mBCl
solution was added to each well containing 100μL of the
medium 20min before measurement. The cells were washed
twice with cold DPBS and the resulting ﬂuorescence was
measured using a DTX 880 multimode detector (Beckman
Coulter, Fullerton, CA, USA) using an excitation wavelength


























































































































































































Figure 2: Eﬀects of gliclazide and NAC on dRib-induced apoptosis of HIT-T15 cells. Cells were preincubated with gliclazide or NAC for
30min and then cultured with 50mMdRib for 24h. Cells were stained with annexin V-FITC (horizontal axis) and PI (longitudinal axis) and
analyzed using ﬂow cytometry. The graph is representative of four independent experiments. (a) Vehicle (0.04% DMSO); (b) 50mMdRib;
(c) 10μM gliclazide + 50mMdRib; (d) 50μM gliclazide + 50mMdRib; (e) 100μM gliclazide + 50mMdRib; (f) 1mM NAC + 50mMdRib.
obtained ﬂuorescence was corrected for intracellular protein
in each well. The ﬁnal results were expressed as the percent-
age of corrected ﬂuorescence compared with vehicle-treated
controls.
Intracellular total glutathione was measured using a
glutathione assay kit (Cayman Chemical Company, Ann
Arbor, MI, USA) based on an enzymatic recycling method
using glutathione reductase. HIT-T15 cells were cultured in
6-well culture plates at a density of 5 × 105 per well. The
cells were treated as described above. Cells were washed
with ice-cold DPBS and sonicated followed by centrifugation
at 10,000g for 15min. The resulting supernatants were
used immediately for measurement of total glutathione.
The concentration of total glutathione was expressed as
micromoles per liter in reference to a standard curve.
2.8. Statistical Analysis. All data were expressed as the mean
± SD. Comparisons between groups were analyzed by one-
way analysis of variance (ANOVA) followed by Duncan’s post
hoc test. All analyses were performed using SPSS software
(version 14.0; SPSS Inc., Chicago, IL, USA), and P<0.05
was considered signiﬁcant.
3. Results
3.1. dRib-Induced Oxidative Damage Is Slightly Reduced by
Gliclazide and Markedly Decreased by NAC. The protective
eﬀects of gliclazide and NAC against dRib-induced cell death
were assessed by trypan blue exclusion tests. A 24-hour
incubation with 35mM dRib induced an extensive death of
HIT-T15 cells. Pretreatment with gliclazide slightly but sig-
niﬁcantly prevented this dRib-induced cell death in a dose-
dependent manner. Addition of 1mM NAC reduced the
level of cell death markedly more than gliclazide treatment
did (Figure 1). Flow cytometry using double staining with
annexin V and PI showed that 50mM dRib stimulation
for 24h produced large increases in the rates of early and
late apoptosis. Pretreatment with 50 or 100μM gliclazide
partially attenuated the dRib-induced apoptosis, and 1mM
NAC almost decreased the apoptosis to that of the vehicle-
treated control (Figure 2, Table 1). ROS production by HIT-
T15 cells was measured following a 6-hour incubation with
50mM dRib in a ﬂow cytometric assay using DHR 123
staining. The dRib stimulation produced a nearly 100-
fold increase in intracellular ROS amounts compared with
the vehicle-treated control. The addition of gliclazide dose
dependently inhibited the rise in intracellular ROS level to4 Oxidative Medicine and Cellular Longevity
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Figure 3: Eﬀects of gliclazide and NAC on the dRib-induced rise
in intracellular ROS levels. Cells were preincubated with gliclazide
or NAC for 30min and then cultured with 50mMdRib for 6h.
Relative ROS levels were quantiﬁed by ﬂow cytometry using the
ROS-sensitive dye DHR 123. Cells were incubated with 5μMD H R
123 during the ﬁnal 30min. The histogram is representative of four
independent experiments.
Table 1:PercentageofannexinV-positivecellsinvehicle-anddRib-
treated HIT-T15 cells, with or without gliclazide or NAC.
Annexin V-positive cells (%)
Control 8.2 ±3.6
50mMdRib alone 72.9 ±5.4∗∗
10μM gliclazide + 50mMdRib 70.9 ± 5.2
50μM gliclazide + 50mMdRib 64.4 ±4.4†
100μM gliclazide + 50mMdRib 57.7 ±8.7††
1m MN A C+5 0m Md R i b 1 3 .3 ±3.4††
Group data from the experiments illustrated in Figure 2 are expressed as the
mean ± SD of four independent experiments. ∗∗P<0.01 versus control
(0.04% DMSO) and †P<0.05 and ††P<0.01 versus 50mMdRib group
evaluated by one-way ANOVA with Duncan’s post hoc test.
as m a l le x t e n t .H o w e v e r ,p r e t r e a t m e n tw i t hN A Cc o m p l e t e l y
blocked this dRib-induced ROS increase (Figure 3, Table 2).
3.2. Gliclazide and NAC Scavenge Fenton Reaction-Driven
Hydroxyl Radicals to a Similar Degree. For direct assessment
of the ROS-scavenging capacities of gliclazide and NAC,
we performed ESR spectroscopy in cell- and dRib-free
conditions. Hydroxyl radicals were generated in a Fenton
Table 2: Relative intracellular ROS levels in vehicle- and dRib-
treated HIT-T15 cells, with or without gliclazide or NAC.
Relative ﬂuorescence
(fold change from control)
Control 1.0
50mMdRib alone 97.2 ±15.7∗∗
10μM gliclazide + 50mMdRib 84.0 ±22.7
50μM gliclazide + 50mMdRib 63.7 ±17.5††
100μM gliclazide + 50mMdRib 50.3 ±9.0††
1mMNAC+50mMdRib 1.7 ±0.3††
Data are expressed as the mean ± SD of four independent experiments.
∗∗P<0.01 versus control (0.04% DMSO) and ††P<0.01 versus
50mMdRib alone evaluated by one-way ANOVA with Duncan’s post hoc
test.
reaction system with DMPO as the trapping agent in a
0.4% ethanol-treated control. The addition of gliclazide
caused signiﬁcant decreases in the levels of DMPO-hydroxyl
radicaladductcomparedwiththecontrol.Pretreatmentwith
NAC also signiﬁcantly reduced the hydroxyl radical signal.
In terms of the capacity for scavenging hydroxyl radicals
generated via the Fenton reaction, there was no signiﬁcant
diﬀerence between gliclazides and NAC (Figure 4).
3.3. NAC but Not Gliclazide Treatment Restores the Level
of Intracellular Glutathione Depleted by dRib. When HIT-
T15 cells were stimulated with various concentrations of
dRib for 6h, intracellular reduced and total glutathione
levels were signiﬁcantly and dose dependently decreased (See
Supplementary Figure1 in Supplementary Material available
online at doi:10.1155/2011/390678). Additions of 10, 50 and
100μM gliclazide never reversed the dRib-induced depletion
of reduced and total glutathione in HIT-T15 cells. However,
pretreatment with 1mM NAC completely restored the dRib-
induced depletions and increased glutathione levels to more
than those seen in the vehicle-treated control (Figure 5).
4. Discussion
This study showed that gliclazide treatment had only minor
protective eﬀects on dRib-induced oxidative damage, but
that NAC treatment almost completely prevented oxidative
damage in HIT-T15 cells. We hypothesize that gliclazide
and NAC have diﬀerent degrees of protection against dRib-
induced oxidative injury because they have diﬀerent antiox-
idative mechanisms. In this experiment, gliclazide could
scavenge hydroxyl radicals generated by a Fenton reaction
but did not regenerate the cellular glutathiones depleted by
dRib. Then, gliclazide only slightly suppressed the dRib-
induced rises in intracellular ROS and apoptosis. However,
NAC possessed both radical-scavenging and glutathione-
regenerating capacities and completely reversed the dRib-
induced oxidative stress and cell death. The elevation of
intracellular glutathione was more important than free
radicalscavenginginpreventingdRib-inducedβ-celldamage
because NAC was more eﬀective than gliclazide in protecting
them against dRib-induced damage. Further, we surmiseOxidative Medicine and Cellular Longevity 5
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Figure 4: Scavenging eﬀects of gliclazide and NAC on hydroxyl radical generation. (a) Representative ESR spectra of DMPO-hydroxyl
radical conjugates measured in the Fenton reaction. (b) Comparison of hydroxyl radical-scavenging activity between gliclazide and NAC
in the reaction as in (a). Reaction mixtures contained 60mM DMPO, 2mM FeSO4,a n d2m MH 2O2 in DPBS with and without various
concentrations of gliclazide or NAC dissolved in 0.4% ethanol. The results are the mean ± SD from four independent experiments. ∗∗P<
0.01 versus vehicle- (0.4% ethanol)-treated control evaluated by one-way ANOVA with Duncan’s post hoc test. NS: no signiﬁcant diﬀerence
from the 1mM NAC group.
that glutathione regeneration is a key mechanism in the
prevention of β-cell damage produced by dRib because
NAC, a glutathione precursor, completely restored the dRib-
induced oxidative damage in HIT-T15 cells.
The progressive decreasein the glucose-lowering eﬀectof
sulfonylureasinpatientswithtype2diabeteswhoseglycemia
responds initially to treatment has been called secondary
failure [10]. In clinical studies, it was demonstrated that
gliclazide had a lower secondary failure rate compared
with other sulfonylureas [11, 12]. This secondary failure is
now recognized as a common progressive form of β-cell
deterioration that develops in the late stage of type 2 diabetes
on any antidiabetic regimen [13, 14]. Oxidative stress is
known to be one of the mechanisms of β-cell failure in
patients with type 2 diabetes. In this research, we could
not elucidate the direct mechanism of the protective eﬀects
of gliclazide against dRib-induced oxidative β-cell damage.
However, we suppose that free radical scavenging would be
one of the mechanisms because gliclazide quenched Fenton
reaction-driven hydroxyl radicals in a cell-free system. In
previous studies, gliclazide proved to be a general free
radical scavenger [4, 5]a n da ne ﬀective antioxidant that
decreasedoxidative stressmarkersin vivo [6–8]. Accordingly,
we attribute the lower secondary failure rate of gliclazide
to its antioxidative eﬀects, which might result from ROS-
scavenging activity.
We demonstrated here that intracellular glutathione
depletion might be the most important mechanism of
dRib-induced oxidative stress in HIT-T15 cells. However,




































































































Figure 5: Eﬀects of gliclazide and NAC on the dRib-induced depletion of intracellular glutathione. The intracellular glutathione levels
were determined by measuring the ﬂuorescent intensity of the GSH-mBCl adduct (a) or using a glutathione assay kit (b). Experimental
conditions were as described in the Section 2. These experiments were performed twice in quadruplicate. ∗P<0.05 and ∗∗P<0.01 versus
control treated with vehicle alone (0.04% DMSO). ††P<0.01 versus 35mMdRib group evaluated by one-way ANOVA with Duncan’s post
hoc test.
intracellular glutathione. Fico et al. [15] reported that dRib
produced oxidative stress-induced apoptosis by inhibiting
the synthesis of GSH and by increasing GSH eﬄux in a
mouse embryonic stem cell line. We could not study the
eﬀect of dRib on glutathione synthesis, but we measured the
extracellular levels of GSH and oxidized glutathione (GSSG)
for indirect assessment of the glutathione eﬄux mediated
by dRib. In our glutathione assay, dRib stimulation did not
elevatetheextracellularGSHandGSSGlevelscomparedwith
control cells in the culture medium alone (data not shown).
Recently, Schmidt et al. [16] also reported that the decline of
intracellular glutathione observed after exposure of cultured
astrocytes to dRib was not accompanied by increases in
extracellular glutathione. Hence, the cellular mechanisms of
dRib-induced glutathione depletion might vary with the cell
types, so more studies for elucidating the exact mechanism
of dRib are clearly needed.
Prolonged exposure to high glucose concentrations can
lead to irreversible β-cell dysfunction and apoptosis, a
phenomenon termed glucose toxicity [17]. Tanaka et al. [18]
showed that NAC, a substrate for glutathione biosynthesis,
prevented glucose toxicity in HIT-T15 cells and Zucker
diabetic fatty rats. It was reported that the overexpression
of glutathione peroxidase that catalyzes the reduction of
hydrogen peroxide by GSH could protect pancreatic islets
against oxidative stress and ameliorate hyperglycemia in
db/db diabetic mice [19, 20]. These results suggest that
glutathione might be a therapeutic target to prevent β-cell
failure in the hyperglycemic conditions seen in subjects with
type 2 diabetes.
Insummary,gliclazidepartiallyattenuateddRib-induced
oxidative stress and apoptosis in HIT-T15 cells. However, its
eﬀects were much smaller than those of NAC because gli-
clazide did not restore the intracellular glutathione depleted
by dRib, unlike NAC. The major protective mechanism
against dRib-induced oxidative damage appears to be the
elevation of intracellular glutathione rather than via ROS
scavenging. Therefore, intracellular glutathione-elevating
agents can completely prevent the dRib-induced oxidative
damage; moreover, they might protect β-cells against glucose
toxicity.
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